A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Ki
PreclinicalCompleted 0 views this week 0 watching
0
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
SARS-CoV-2
Conditions
SARS-CoV-2
Trial Timeline
Apr 11, 2022 → Aug 14, 2022
NCT ID
NCT05367908About A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Ki
A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Ki is a preclinical stage product being developed by Moderna for SARS-CoV-2. The current trial status is completed. This product is registered under clinical trial identifier NCT05367908. Target conditions include SARS-CoV-2.
What happened to similar drugs?
4 of 20 similar drugs in SARS-CoV-2 were approved
Approved (4) Terminated (1) Active (16)
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05367908 | Preclinical | Completed |
Competing Products
20 competing products in SARS-CoV-2
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1010 | Moderna | Phase 1 | 0 |
| mRNA-1273 | Moderna | Preclinical | 0 |
| mRNA-1273 | Moderna | Phase 1 | 0 |
| mRNA-1283 | Moderna | Phase 1 | 0 |
| mRNA-1273 | Moderna | Preclinical | 0 |
| mRNA-1083 Composition 1 Dose A Lot A | Moderna | Phase 2 | 0 |
| mRNA-1273.214 | Moderna | Phase 2 | 0 |
| SPIKEVAX | Moderna | Preclinical | 0 |
| mRNA-1273 | Moderna | Phase 3 | 0 |
| mRNA-1273 | Moderna | Phase 3 | 0 |
| mRNA-1273 | Moderna | Preclinical | 0 |
| mRNA-1083.1 | Moderna | Phase 2 | 0 |
| SPIKEVAX Bivalent | Moderna | Preclinical | 0 |
| mRNA-1083 | Moderna | Phase 3 | 0 |
| mRNA-1273 | Moderna | Phase 2 | 0 |
| mRNA-1073 | Moderna | Phase 2 | 0 |
| mRNA-1273 | Moderna | Phase 3 | 0 |
| mRNA-1273 | Moderna | Preclinical | 0 |
| mRNA-1273.211 | Moderna | Phase 3 | 0 |
| SPIKEVAX (mRNA-1273) | Moderna | Preclinical | 0 |